纳武单抗在晚期非小细胞肺癌治疗中的应用

国际肿瘤学杂志››2019,Vol. 46››Issue (5): 295-298.doi:10.3760/cma.j.issn.1673-422X.2019.05.009

纳武单抗在晚期非小细胞肺癌治疗中的应用

刘冬祺¹，陈润泽²，刘禹含¹，周欢¹

¹大连医科大学附属第二医院肿瘤三科116000；²大连理工大学莱斯特国际学院，盘锦124221

收稿日期:2019-01-21出版日期:2019-05-08发布日期:2019-06-14
通讯作者:周欢 E-mail:zhouhuan8103@126.com
基金资助:

辽宁省自然科学基金（2015020656）

Application of the Nivolumab in the treatment of advanced non-small cell lung cancer

Liu Dongqi¹, Chen Runze², Liu Yuhan¹, Zhou huan¹

¹Third Department of Oncology, Second Hospital of Dalian Medical University, Dalian 116000, China;²Leicester International Institute, Dalian University of Technology, Panjin 124221, China

Received:2019-01-21Online:2019-05-08Published:2019-06-14
Contact:Zhou Huan E-mail:zhouhuan8103@126.com
Supported by:

National Science Foundation of Liaoning Province of China (2015020656)

摘要/Abstract

摘要：我国肺癌发病率及死亡率居全部恶性肿瘤首位，与非小细胞肺癌（NSCLC）相关的治疗研究如靶向治疗、免疫治疗也是近年来的研究热点。纳武单抗是第1个进入临床试验的程序性死亡蛋白-1抑制剂，也是中国首个获批上市的肿瘤免疫治疗药物。2018年6月，纳武单抗注射液在国内上市，用于晚期NSCLC患者的二线治疗，开启了我国肺癌治疗的新时代。对纳武单抗治疗NSCLC相关的临床研究进行回顾分析，归纳其用法、用量、主要不良反应，将为临床应用提供帮助，为患者带来更大的益处。

关键词:癌,非小细胞肺,免疫治疗,纳武单抗

Abstract:Lung cancer has the highest morbidity and mortality among malignant tumors in our country. The treatment researches related to nonsmall cell lung cancer (NSCLC) such as targeted therapy and immunotherapy are the research hotspots in recent years. Nivolumab is the first programmed death-1 (PD-1) inhibitor which is allowed to enter clinical trials, and it is also the first approved drug for tumor immunotherapy in China. In June 2018, Nivolumab injection was marketed in China, and it was used in the secondline treatment for the patients with advanced NSCLC, opened up a new era of the lung cancer treatment in our country. Review the clinical research related to the Nivolumab and NSCLC, summarizing usage, dosage, adverse reactions, will provide a help for clinical application, bring more benefits for patients at the same time.

Key words:Carcinoma, non-small-cell lung,Immunotherapy,Nivolumab

刘冬祺，陈润泽，刘禹含，周欢. 纳武单抗在晚期非小细胞肺癌治疗中的应用[J]. 国际肿瘤学杂志, 2019, 46(5): 295-298.

Liu Dongqi, Chen Runze, Liu Yuhan, Zhou huan. Application of the Nivolumab in the treatment of advanced non-small cell lung cancer[J]. Journal of International Oncology, 2019, 46(5): 295-298.

参考文献

［1］ Lim JS, Soo RA. Nivolumab in the treatment of metastatic squamous nonsmall cell lung cancer: a review of the evidence［J］. Ther Adv Respir Dis, 2016, 10(5): 444-454. DOI: 10.1177/1753465816661091. ［2］ Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment［J］. J Immunother, 2014, 37(3): 187-191. DOI: 10.1097/CJI.0000000000000024. ［3］ Hwang YY, Khong PL, Kwong YL. Lowdose nivolumab induced remission in refractory classical Hodgkin lymphoma［J］. Ann Hematol, 2017, 96(7): 1219-1220. DOI: 10.1007/s00277-017-3007-9. ［4］ El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial［J］. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2. ［5］ Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates［J］. Cancer Immunol Res, 2014, 2(9): 846-856. DOI: 10.1158/2326-6066. ［6］ Gettinger S, Horn L, Jackman D, et al. Five-year followup of nivolumab in previously treated advanced non-small cell lung cancer: results from the CA209-033 study［J］. J Clin Oncol, 2018, 36(17): 1675-1684. DOI: 10.1200/JCO.2017.77.0412. ［7］ Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer［J］. N Engl J Med, 2015, 373(2): 123-135. DOI: 10.1056/NEJMoa1504627. ［8］ Borghaei H, PazAres I, Horn I, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small cell lung cancer［J］. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643. ［9］ Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced nonsmallcell lung cancer: twoyear outcomes from two randomized, openlabel, phase Ⅲ trials (CheckMate 017 and CheckMate 057)［J］. J Clin Oncol, 2017, 35(35): 3924-3933. DOI: 10.1200/JCO.2017.74.3062. ［10］ Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced nonsmallcell lung cancer (CheckMate 017 and CheckMate 057): 3-year up date and outcomes in patients with liver metastases［J］. Ann Oncol, 2018, 29(4): 959-965. DOI: 10.1093/annonc/mdy041. ［11］ Lu S. Nivolumab (nivo) vs Docetaxel (doce) in Chinese patients (pts) with previously treated advanced (adv) nonsmallcell lung cancer (NSCLC): results of CheckMate078［R］. CSCO 2018. ［12］ Rizvi NA, Mazières J, Planchard D, et al. Activity and safety of nivolumab, an antiPD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous nonsmallcell lung cancer (CheckMate 063): a phase 2, singlearm trial［J］. Lancet Oncol, 2015, 16(3): 257-265. DOI: 10.1016/S1470-2045(15)70054-9. ［13］ Spigel DR, Mcleod M, Hussein MA, et al. 1297ORandomized results of fixedduration (1-yr) vs continuous nivolumab in patients (pts) with advanced nonsmall cell lung cancer(NSCLC)［J］. Ann Oncol, 2017, 28(Suppl_5). DOI: 10.1093/annonc/mdx380.002. ［14］ Carbone DP, Reck M, PazAres L, et al. FirstLine nivolumab in stage IV or recurrent non-small-cell lung cancer［J］. N Engl J Med, 2017, 376(25): 2415-2426. DOI: 10.1056/NEJMoa1613493. ［15］ Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as firstline treatment for advanced nonsmallcell lung cancer (CheckMate012): results of an openlabel, phase 1, multicohort study［J］. Lancet Oncol, 2017, 18(1): 31-34. DOI: 10.1016/S1470-2045(16)30624-6. ［16］ Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden［J］. N Engl J Med, 2018, 378(22): 2093-2104. DOI: 10.1056/NEJMoa1801946. ［17］ Ready N, Hellmann MD, Awad MM, et al. Firstline nivolumab plus ipilimumab in advanced nonsmallcell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers［J］. J Clin Oncol, 2019, 37(12): 992-1000. DOI: 10.1200/JCO.18.01042. ［18］ Gordon R, Kasler MK, Stasi K, et al. Checkpoint inhibitors: common immunerelated adverse events and their management［J］. Clin J Oncol Nurs, 2017, 21(2): 45-52. DOI: 10.1188/17.CJON.S2.45-52. ［19］ Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature［J］. Cancer, 2018, 124(2): 271-277. DOI: 10.1002/cncr.31043. ［20］ Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of antiPD-1 antibody in cancer［J］. N Engl J Med, 2012, 366(26): 2443-2454. DOI: 10.1056/NEJMoa1200690. ［21］ Waterhouse D, Horn L, Reynolds C, et al. Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153［J］. Cancer Chemother Pharmacol, 2018, 81(4): 679-686. DOI: 10.1007/s00280-018-3527-6.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维.Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[4]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[6]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华.炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[7]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[8]	顾芳萌, 徐晨阳, 雷大鹏.人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[9]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[10]	王昆, 周中新, 臧其威.血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[11]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇.信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[12]	姚益新, 沈煜霖.血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[13]	胡婷婷, 王越华.电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[14]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[15]	严爱婷, 王翠竹, 刘春桂, 鲁小敏.卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.